Postcardiac Surgery Euglycemic Diabetic Ketoacidosis in Patients on Sodium-Glucose Cotransporter 2 Inhibitors.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of cardiothoracic and vascular anesthesia"
DOI: 10.1053/j.jvca.2023.01.041
Abstract: OBJECTIVES To evaluate sodium-glucose cotransporter 2 inhibitors (SGLT2i) use and complications (euglycemic diabetic ketoacidosis [eDKA] rate, mortality, infection, hospital, and cardiovascular intensive care unit [CVICU] length of stay [LOS]) in patients undergoing cardiac surgery. DESIGN… read more here.
Keywords: surgery; glucose cotransporter; cardiac surgery; sglt2i use ... See more keywords
SGLT2i reduces risk of developing HCC in patients with co-existing T2D and CHB infection - A territory-wide cohort study in Hong Kong.
Sign Up to like & getrecommendations! Published in 2023 at "Hepatology"
DOI: 10.1097/hep.0000000000000404
Abstract: BACKGROUND AND AIMS Type 2 diabetes (T2D) and chronic hepatitis B infection (CHB) are risk factors of hepatocellular carcinoma (HCC). Sodium glucose co-transporter 2 inhibitors (SGLT2i) inhibit HCC oncogenesis in preclinical studies. However, clinical studies… read more here.
Keywords: hcc; t2d chb; existing t2d; sglt2i use ... See more keywords